Diagnosis and Management of Exocrine Pancreatic Insufficiency
- 468 Downloads
Purpose of review
Recent studies have documented that many patients with pancreatic exocrine insufficiency (EPI) are not identified and are not treated with appropriate dosages of pancreatic enzyme replacement therapy. This review will summarize the approach to diagnosis, treatment, and monitoring for treatment effect and complications in patients with exocrine insufficiency.
While chronic pancreatitis is the most commonly identified cause of EPI, pancreatic cancer and pancreatic surgery are increasingly important. The diagnosis of EPI remains challenging, but fecal elastase is the most clinically useful test. Treatment requires an understanding of the appropriate dosage and timing of enzyme replacement, but recent studies show that clinicians often do not have this understanding. Monitoring and prevention of complications of EPI is increasingly important, particularly osteopenia and osteoporosis. In those that fail to respond, coexistent small intestinal bacterial overgrowth should be considered.
Many clinicians do not consider EPI in the differential diagnosis, and patients with EPI are routinely undertreated in the USA. Appropriate identification of those at risk and use of appropriate enzyme therapy, along with monitoring for metabolic complications of EPI, are essential to provide effective care for these patients.
KeywordsChronic pancreatitis Pancreatic cancer Exocrine pancreatic insufficiency
Compliance with ethical standards
Conflict of interest
Chris E Forsmark declares that he has no conflict of interest.
Human and animal rights and informed consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 8.• Hart PA, Bellin MD, Anderson DK, et al. Type 3c (pancreaticogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. Lancet Gastroenterol Hepatol. 2016;1:226–37. This review describes the complex connections between chronic pancreatitis, pancreatic cancer, and pancreatic endocrine insufficiency.CrossRefPubMedPubMedCentralGoogle Scholar
- 16.• Hollemans RA, Hallensleben NDL, Mager DJ, et al. Pancreatic exocrine insufficiency following acute pancreatitis: systematic review and study-level meta-analysis. Pancreatology. 2018;18:253–62. A review of the relatively common occurrence of EPI even in the setting of acute pancreatitis.CrossRefPubMedGoogle Scholar
- 17.Lee HW, Moon SH, Kim MH, et al. Relapse rate and predictors of relapse in a large single center cohort of type 1 autoimmune pancreatitis: long-term follow-up results after steroid therapy with short-duration maintenance treatment. J Gastroenterol. 2018;53(8):967–77.Google Scholar
- 27.• Vanga RR, Tansel A, Sidiq S, et al. Diagnostic performance of measurement of fecal elastase-1 in detection of exocrine pancreatic insufficiency: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018; https://doi.org/10.1016/j.cgh.2018.01.027. A detailed review of the accuracy, and inaccuracy, of testing for EPI.PubMedCrossRefGoogle Scholar
- 31.• Duggan SN, Smyth ND, Murphy A, MacNaughton D, O'Keefe SJD, Conlon KC. High prevalence of osteoporosis in patients with chronic pancreatitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014;12:219–28. A nice review of how common and how important bine disease is in patients with EPI.CrossRefPubMedGoogle Scholar
- 32.de la Iglesia-Garcia D, Huang W, Szatmary P, Baston-Rey I, et al. Efficacy of pancreatic enzyme replacement therapy in chronic pancreatitis: systematic review and meta-analysis. Gut. 2017;66:1474–86.Google Scholar
- 35.de la Iglesia-Garcia D, Vallejo-Senra N, Iglesias-Garcia J, et al. Increased risk of mortality associated with pancreatic exocrine insufficiency in patients with chronic pancreatitis. J Clin Gastroenterol. 2017; https://doi.org/10.1097/MCG.0000000000000917.
- 45.Forsmark CE, Tang G, Tuft M, et al. Oral pancreatic enzyme replacement therapy (PERT) in patients with pancreatic cancer (PCa) is infrequent and suboptimal: a national level analysis. (abstract). Pancreas. 2017;46:1400.Google Scholar
- 47.Ni Chonchubhair HM, Bashir Y, Dobson M, et al. The prevalence of small intestinal bacterial overgrowth in non-surgical patients with chronic pancreatitis and pancreatic exocrine insufficiency (PEI). Pancreatology. 2018;18:379–85.Google Scholar
- 48.DiMagno MJ, Forsmark CE. Chronic pancreatitis and small intestinal bacterial overgrowth. Pancreatology. 2018;18:360–2.Google Scholar